science wire

« BACK

Pharmacology



Results 1201 - 1250 of 1868.


Health - Pharmacology - 30.08.2016
FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine   Erelzi is approved for all indications included in the reference product's label  

Pharmacology - Health - 25.08.2016
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo There are currently very limited treatment options for SPMS, a form of MS associated with gradual worsening of symptoms and accumulation of disability, independent of relapses EXPAND is the largest study ever conducted in SPMS, and is part

Pharmacology - Chemistry - 23.08.2016
A patent for oxidised fat
A patent for oxidised fat
ETH researchers have synthesised fatty acids in the laboratory that result from oxidative stress in the body. The laboratory variants turned out to be more potent anti-inflammatories than the natural ones, and have now been patented. It is a hotly debated, highly researched subject that has taken on the semblance of a religious war: what are good and what are bad fats?

Pharmacology - Health - 03.08.2016
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option   Results from Phase III MONALEESA-2 trial of LEE011 in combination with letrozole in postmenopausal women who had re

Health - Pharmacology - 02.08.2016
Alcon achieves US approval for CyPass Micro-Stent, a micro invasive surgical device to treat glaucoma
US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma   The CyPass Micro-Stent is designed to reduce i

Environment - Pharmacology - 27.07.2016
New approach for environmental test on livestock drugs
New approach for environmental test on livestock drugs
Livestock medications can impair beneficial organisms that break down dung. Too high a dosage of ivermectin, a common drug against parasites, harms coprophilous organisms, for instance. The toxicity of new livestock medications therefore needs to be verified in ecotoxicological tests with individual animal species such as the common yellow dung fly, the barn fly or a dung beetle.

Health - Pharmacology - 26.07.2016
Chinese Drug Tribendimidine a Promising Drug Candidate Against Liver Fluke
Chinese Drug Tribendimidine a Promising Drug Candidate Against Liver Fluke
Already 100mg of the Chinese drug candidate tribendimidine helps patients to get rid of a helminth infection caused by Opisthorchis viverrini according to a clinical study conducted by the Swiss Tropical and Public Health-Institute (Swiss TPH) and the National Institute of Public Health (NIOPH) in Lao PDR.

Economics / Business - Pharmacology - 19.07.2016
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects Q2 net sales were flat (0% cc ) as Growth Produc

Pharmacology - Health - 13.07.2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product                                                                

Pharmacology - Health - 07.07.2016
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirmatory cl

Health - Pharmacology - 30.06.2016
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage   Advanced SM is rare and has a poor prognosis , ; current

Physics - Pharmacology - 29.06.2016
To starve a tumour
To starve a tumour
Forty years of research on cell growth PSI researcher Kurt Ballmer-Hofer is concerned with the question of how tumours could be starved by preventing the development of blood vessels.

Pharmacology - Health - 28.06.2016
Roche’s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Roche's marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine seeking marketing authorisation for both relapsing and primary progressive multiple sclerosis (MS) FDA grants Priority Review Designation for OCREVUS Biologics License Application (BLA) Roche announced today that the European Medicines Agency (EMA) has validated the company's

Health - Pharmacology - 28.06.2016
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline   Collaboration will co-develop Xencor's two T

Health - Pharmacology - 22.06.2016
Timely use of Novartis’ Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)   Cardiology experts highlight risk of delaying broad adoption of Entresto in patients with HFrEF and call for efforts to accele

Pharmacology - Health - 15.06.2016
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundati

Health - Pharmacology - 10.06.2016
Novartis presents data showing Jakavi is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi (ruxolitinib) vs BAT   RESPONSE-2 complements data from pivota

Health - Pharmacology - 10.06.2016
Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder
EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially seri

Pharmacology - Health - 09.06.2016
New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products
Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.   Sandoz' biosimilar rituximab candidate shows PK bioequivalence  and similar pharmacodynamics (PD), safety, efficacy and immunogenicity.

Pharmacology - Health - 08.06.2016
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx at two years had no radiographic progression in the spine or joints , respectively ,     Cosentyx may

Pharmacology - Health - 08.06.2016
Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment   Migraine is a leading cause of disability, affec

Health - Pharmacology - 06.06.2016
Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer
The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar + Mekinist combination therapy was 9 months   Efficacy analyses also presented for INC280 (capmatinib) in cM

Health - Pharmacology - 06.06.2016
Novartis combination therapy Tafinlar + Mekinist demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Novartis combination therapy Tafinlar + Mekinist demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma Study is longest Ph III survival follow-up to date of

Health - Pharmacology - 05.06.2016
Roche’s cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer
Roche's cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer New survival results also reported from study group with previously tr

Pharmacology - Health - 04.06.2016
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna
In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the > 50% lower limit of the 95% confidence interval   ENESTop met primary endpoint with 57.9% of eligible patients who had switched to Tasigna from Glivec maintaining TFR for 48 weeks after treatment cessation   First results from clinical program

Health - Pharmacology - 02.06.2016
Novartis drug Afinitor receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET   Nonfunctional GI and lung NET are rare

Pharmacology - Health - 31.05.2016
Roche’s subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia
Roche's subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia Subcutaneous (SC) formulation of MabThera saves time and eases treatment burden

Pharmacology - Health - 25.05.2016
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
Outlines actions underway to accelerate launch of Entresto , including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx Highlights leading pipeline of second

Health - Pharmacology - 24.05.2016
Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label Sandoz'

Health - Pharmacology - 21.05.2016
Novartis’ Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals US guidelines now recommend Entresto as standard of care

Health - Pharmacology - 19.05.2016
Novartis announces investment in FortiHFy clinical program of Entresto and heart failure
Forti fying H eart F ailure clinical evidence and patient qualit y of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of life benefits and real world evidence with Entresto   Investigators and patients from over 50 countries to participate over 5 years - Novartis today announced the establishment

Pharmacology - Health - 19.05.2016
Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer
Phase III study of Roche's Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer First investigational head-to-head study of Alecensa versus crizotinib in people with advanced ALK-positive non-small cell lung cancer (NSCLC) Roche today announced that Alecensa , an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death (progression free survi

Health - Pharmacology - 18.05.2016
MONALEESA-2 trial of Novartis’ LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer Independent Data Monitoring Committee recommends st

Pharmacology - Health - 18.05.2016
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna both in front-line and second-line following Glivec *   First genomic analysis and 3-year efficacy/

Health - Pharmacology - 15.05.2016
Major study published in NEJM confirms Novartis’ Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations
FLAME study showed consistent superiority of Ultibro Breezhaler over Seretide across exacerbation outcomes, lung function and health-related quality of life in COPD patients    Ultibro Breezhaler also significantly reduced the rate and prolonged the time to the first moderate or severe exacerbation, compared to Seretide   Results published in the New England Journal of Medicine are anticipated to have important implications for the care of peopl

Health - Pharmacology - 29.04.2016
Novartis drug Afinitor recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional GI

Health - Pharmacology - 28.04.2016
A New Discovery in the Fight against Cancer: Tumor Cells Switch to a Different Mode
A New Discovery in the Fight against Cancer: Tumor Cells Switch to a Different Mode
When medication is used to shut off the oxygen supply to tumor cells, the cells adapt their metabolism in the medium term - by switching over to producing energy without oxygen. This observation by biomedical scientists at the University of Basel and University Hospital Basel could be used for treatments that can inhibit tumor growth in the long term, as the researchers report in the latest issue of the journal Cell Reports.

Pharmacology - Health - 27.04.2016
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Subject to approvals, Ilaris will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF   Designations support potential expedite

Economics / Business - Pharmacology - 21.04.2016
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Net sales up 1% (cc ), as Growth Products offset Gleevec impact Growth Products grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow strongl

Pharmacology - Health - 21.04.2016
Hitting cancer from the inside
Hitting cancer from the inside
Most cancer cells carry unique receptors on their surface. Because the receptors extend into the cell's interior, they act as intermediaries between the outside and the inside.

Health - Pharmacology - 20.04.2016
Novartis drug Afinitor significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients   Seizures are the most common TSC-related neurological condition, yet about 60% of patients don't attain seizure control with available anti-epileptic therapies   Results presented at AAN will be discussed with health authorities for potential worldwide regulatory filings - Novartis today

Health - Pharmacology - 12.04.2016
Roche to present new data about multiple sclerosis
Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms of multiple sclerosis New analyses showing superior efficacy of ocrelizumab across clinical and subclinical outcomes compared with interferon beta- 1a (Rebif ) in people with relapsing MS and compared with placebo in primary progressive MS will be presented Roche announced today th

Health - Pharmacology - 12.04.2016
Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia
Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia   Venclexta is designed to help restore a cell's ability to self-destruct and is the first medicine of its kind to be approved Roche announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta(TM) (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.

Health - Pharmacology - 11.04.2016
FDA grants priority review for Roche’s cancer immunotherapy atezolizumab in specific type of lung cancer
FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accep

Pharmacology - Health - 07.04.2016
Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies   Two formulations approved: once-daily table

This site uses cookies and analysis tools to improve the usability of the site. More information. |